2-Methyl-2,3-dihydro-indole-1-carboxylic acid ethyl ester | 67902-43-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-Methyl-2,3-dihydro-indole-1-carboxylic acid ethyl ester
• 英文别名: Ethyl 2-methyl-1-indolinecarboxylate；ethyl 2-methyl-2,3-dihydroindole-1-carboxylate
• CAS: 67902-43-6
• 化学式: C₁₂H₁₅NO₂
• mdl: MFCD06004083
• 分子量: 205.257
• InChiKey: JBZMYSYCWRTAJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-Carbethoxy-2,3-dihydro-2-<(phenylseleno)methyl>indole 在 三苯基氢化锡 作用下， 以 甲苯 为溶剂， 反应 4.0h， 以80%的产率得到2-Methyl-2,3-dihydro-indole-1-carboxylic acid ethyl ester
  参考文献：
  名称：

  Organic tellurium and selenium chemistry. Reduction of tellurides, selenides, and selenoacetals with triphenyltin hydride

  摘要：

  DOI：

  10.1021/ja00533a024

文献信息

• C(sp ³ )−H Arylation Promoted by a Heterogeneous Palladium‐N‐Heterocyclic Carbene Complex in Batch and Continuous Flow
  作者：Francesco Ferlin、Ioannis Anastasiou、Nihad Salameh、Takeru Miyakoshi、Olivier Baudoin、Luigi Vaccaro

  DOI：10.1002/cssc.202102736

  日期：2022.3.22

  C−H arylation: Batch and continuous-flow protocols are developed for the first time for intramolecular Pd0-catalyzed C(sp3)−H activation/cyclization using a heterogeneous reusable palladium(II)-bis(N-heterocyclic carbene) catalyst.

  C−H 芳基化：首次开发了使用非均相可重复使用的钯(II)-双(N-杂环卡宾)催化剂进行分子内 Pd 0催化的 C(sp 3 )−H 活化/环化的批量和连续流方案。
• COMPOUNDS AND METHODS OF TREATING HYPERTENSION
  申请人：Protter Andrew Asher

  公开号：US20140303144A1

  公开（公告）日：2014-10-09

  Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α 2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α 2B . The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

  本文介绍了氢化吡啶[4,3-b]吲哚、吡啶[3,4-b]吲哚和氮杂七环[4,5-b]吲哚。这些化合物可以与肾上腺素受体α2B结合并对其产生拮抗作用。这些化合物还可以与肾上腺素受体α2B结合并对其产生拮抗作用。这些化合物可以用于治疗，例如：（i）降低血压和/或（ii）促进肾脏血流和/或（iii）减少或抑制钠的重吸收。这些化合物还可以用于治疗对降低血压有反应或预计会有反应的疾病或病况。特别描述了这些化合物用于治疗心血管和肾脏疾病。
• FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE
  申请人：Chakravarty Sarvajit

  公开号：US20130210803A1

  公开（公告）日：2013-08-15

  This disclosure is directed to fused tetracyclic pyrido[4,3-b]indoles and pyrido[3,4-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及熔合四环吡啶[4,3-b]吲哚和吡啶[3,4-b]吲哚。还提供了包含这些化合物的制药组合物，以及使用这些化合物进行多种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• COMPOUNDS AND METHODS OF TREATING DIABETES
  申请人：Protter Andrew Asher

  公开号：US20140228353A1

  公开（公告）日：2014-08-14

  Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α 2A . The compounds may also bind to and are an antagonist of the adrenergic receptor α 2B ; or the compounds are not antagonists of the adrenergic receptor α 2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

  介绍了氢化吡咯[4,3-b]吲哚、吡咯[3,4-b]吲哚和氮杂七环[4,5-b]吲哚。这些化合物可以结合并拮抗肾上腺素α2A受体。这些化合物也可以结合并拮抗肾上腺素α2B受体；或者这些化合物不是肾上腺素α2B受体的拮抗剂，并且这些化合物与第二种预计可以降低血压的药物一起使用。这些化合物可以用于治疗，例如调节血糖水平，增加胰岛素分泌并治疗对胰岛素产生增加反应的疾病或状况。特别描述了使用这些化合物治疗2型糖尿病的方法。
• CLIVE D. L. J.; CHITTATTU G. J.; FARINA V.; KIEL W. A.; MENCHEN S. M.; RU+, J. AMER. CHEM. SOC., 1980, 102, NO 13, 4438-4447
  作者：CLIVE D. L. J.、 CHITTATTU G. J.、 FARINA V.、 KIEL W. A.、 MENCHEN S. M.、 RU+

  DOI：——

  日期：——